Fierce Healthcare January 29, 2019
Paige Minemyer

CMS’ innovation center has unveiled several new payment models in recent months, but none has sparked quite the reaction of one of the center’s latest models for drugs, the International Pricing Index.

Medicare beneficiaries may not understand the finer points of financial risk or population health management, said Adam Boehler, deputy administrator at the Centers for Medicare & Medicaid Services and director of the Center for Medicare & Medicaid Innovation.

But they sure understand when they hear that prices for drugs in the U.S. can be as much as four or five or six times higher than those in developed countries, Boehler said.

Boehler even got a call from his own mother about it.

“Right away, it got...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: CMS, Govt Agencies, Insurance, Medicare, Pharma, Pricing / Spending, Provider
How Will Walgreens’ Expansion into Specialty Pharmacy Affect the Industry?
BMS plans $1.5B in cuts through '25, with 2000-plus layoffs
Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report
Sanofi crosses Sjögren's off $5B drug's hit list after phase 2
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth

Share This Article